Skip to main content

Advertisement

Table 1 Patient characteristics

From: Risks of postoperative paresis in motor eloquently and non-eloquently located brain metastases

   Eloquent Non-eloquent
Number of patients   56 150
Preoperative paresis   57.0% 47.3%
Sex Male 32 (57.0%) 72 (48.0%)
Female 24 (43.0%) 78 (52.0%)
Median age ± SD   61.4 ± 13.1 years 60.9 ± 11.9 years
Location Precentral 32.0% -
Frontal 27.0% 30.0%
Subcortical 22.0% -
Postcentral 14.0% -
Cerebellar - 20.0%
Occipital - 15.3%
Temporomesial - 13.3%
Parietal w/o postcentral gyrus - 9.3%
Other - 12.1%
Primary tumor NSCLC 30.4% 29.5%
Breast 21.4% 20.1%
Melanoma 8.9% 10.7%
Colon 7.1% 8.7%
RCC 7.1% 10.1%
CUP 7.1% 4.0%
Ovarian 5.4% 2.7%
Esophageal 3.6% 4.7%
Seminoma 1.8% 0.7%
Paranasial sinus 1.8% 0.7%
Urothelial 1.8% 0.7%
SCLC 1.8% 2.0%
Uterine sarcoma 1.8% 0.7%
Gastric - 1.3%
Larynx - 1.3%
Gall bladder - 0.7%
Parotid gland - 0.7%
Prostate - 0.7%
Number of brain metastases 1 57.0% 56.7%
2 18.0% 18.0%
3 11.0% 10.3%
>3 14.0% 15.0%
RPA score 1 14.0% 15.0%
2 64.0% 65.0%
3 22.0% 20.0%
Preoperative therapy Rtx 5.4% 2.7%
(n = 150) Ctx 30.4% 34.0%
Rtx + Ctx 14.3% 19.3%
  1. Overview of all enrolled patients including sex, preoperative existing deficit, primary tumor, and preoperative therapy). Ctx, Chemotherapy; CUP, Carcinoma of unknown primary; NSCLC, Non small cell lung cancer; RCC, Renal cell cancer; Rtx, radiotherapy; SCLC, Small cell lung cancer; SD, Standard deviation.